Showing 3591-3600 of 7510 results for "".
- Systematic Review Explores Thiamidol’s Impact on Hyperpigmentationhttps://practicaldermatology.com/news/systematic-review-explores-thiamidols-impact-on-skin-discoloration/2468460/Data from a recent systematic review of 14 clinical studies shows topical isobutylamido thiazolyl resorcinol (ITR) provides statistically significant improvement in various types of hyperpigmentation, including melasma, post-inflammatory hyperpigmentation (PIH), and UV-induced hyperpigmentation.<
- Hair Follicle-Derived KCs From AD Patients Could Help Study Inflammationhttps://practicaldermatology.com/news/hair-follicle-derived-kcs-ad-patients-could-help-study-inflammation/2468385/A new JID Innovations study suggests that hair follicle-derived keratinocytes (KCs) from patients with atopic dermatitits (AD) represent a useful model system to study AD-related inflammation in a personalized in vitro model. Researchers at Germany’s University Hospital Schleswig-Holstein
- Analysis: Higher Infection and Acne Risks with JAK Inhibitors in ADhttps://practicaldermatology.com/news/analysis-higher-infection-and-acne-risks-jak-inhibitors-ad/2468381/Researchers for a new analysis have provided a data and analytics framework for the evaluation of the safety of immune-modulating drugs (IMDs) in treating atopic dermatitis (AD). The study authors designed the system to generate timely, high-quality evidence using sequential propensity sco
- Study Links Radioactive Iodine Therapy to Increased Melanoma Riskhttps://practicaldermatology.com/news/study-links-radioactive-iodine-therapy-increased-melnoma-risk/2468325/A new study found elevated risk of melanoma and other nonkeratinocyte skin cancers in patients with primary thyroid cancer who received radioactive iodine therapy, particularly in the head and neck region. In the JAMA Network Open article “Development of Melanoma and Other Nonkeratinocyte
- INTEGUMENT Trials: Once-Daily Roflumilast Cream Reduces AD Symptomshttps://practicaldermatology.com/news/integument-trials-once-daily-roflumilast-cream-reduces-ad-symptoms/2468245/Roflumilast cream, 0.15%, significantly improved symptoms of mild to moderate atopic dermatitis (AD) in two phase 3 clinical trials. Researchers for the INTEGUMENT-1 and INTEGUMENT-2, publishing their results in JAMA Dermatology, evaluated the efficacy and safety of roflumilast cr
- EADV Presentation to Highlight New IL-13/IL-31 Bispecific Antibodyhttps://practicaldermatology.com/news/eadv-presentation-highlight-new-il-13il-31-bispecific-antibody/2468228/Data from a preclinical study of ZL-1503, an IL-13/IL-31 bispecific antibody for the treatment of atopic dermatitis (AD), will be presented in a late-breaking oral presentation at the European Academy of Dermatology and Venerology Congress (EADV) 2024 taking place September 25-28 in Amsterdam, Ne
- Researchers Analyze Social Media Posts on JAK Inhibitorshttps://practicaldermatology.com/news/researchers-analyze-social-media-posts-jak-inhibitors/2468227/An analysis of social media posts concluded that patients are most concerned about the efficacy and side effects of JAK inhibitors and issues regarding access to them, according to a new Archive of Dermatological Research article by members of the University of Nebraska Medical Center’s Departmen
- IGSRT Shows High Recurrence-Free Rates in Non-Melanoma Skin Cancerhttps://practicaldermatology.com/news/igsrt-shows-high-recurrence-free-rates-non-melanoma-skin-cancer/2468185/Nonmelanoma skin cancer (NMSC) treated with Image-Guided Superficial Radiation Therapy (IGSRT) showed consistently high freedom from recurrence rates, regardless of patient age or sex, according to a new analysis. The large retrospective cohort study, published in Geriatrics and c
- Cord Blood Biomarkers and TEWL Predict Atopic Dermatitis in Infantshttps://practicaldermatology.com/news/cord-blood-biomarkers-and-tewl-predict-atopic-dermatitis-infants/2468171/A prospective study reports that elevated levels of CCL17 and IL-31 in cord blood, along with increased transepidermal water loss (TEWL) at the anterior cubital fossa, could help identify infants at higher risk of developing atopic dermatitis (AD) within their first year of life. The study
- Lebrikizumab Shows Significant Improvement in Atopic Dermatitishttps://practicaldermatology.com/news/lebrikizumab-shows-significant-improvement-atopic-dermatitis/2468116/Lebrikizumab monotherapy showed significant improvements in clinical signs, symptoms, and quality of life in patients with moderate-to-severe atopic dermatitis over 16 weeks, according to new research. The analysis of two phase 3 placebo-controlled studies (ADvocate1 and ADvocate2) looked